Acute Effects of Growth Hormone on Vascular Function in Human Subjects
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
GH is involved in the long-term regulation of peripheral vascular resistance and vascular reactivity. We determined whether GH plays a role in the acute regulation of vascular function in humans. The acute vascular effects of GH were studied in eight healthy subjects according to a double-blind, placebo-controlled design. Forearm blood flow (FBF), vascular resistance, and nitric oxide (NO) production were monitored during a 4-h infusion of GH into the brachial artery at a rate chosen to raise local GH to stress levels (approximately 40 ng/ml). During GH infusion, FBF rose 75% (P < 0.05), whereas forearm vascular resistance decreased comparably (P < 0.05). These changes were paralleled by augmented forearm release of NO (P < 0.02). GH heightened the response of FBF to the endothelium-dependent vasodilator acetylcholine (Ach; P < 0.02). With the highest Ach dose, FBF reached 30.4 +/- 4.2 and 16.9 +/- 3.1 ml/dl x min in the GH and placebo studies, respectively (P < 0.005). The slopes of the dose-response curves also differed markedly (0.45 +/- 0.07 and 0.25 +/- 0.05 ml/dl x min/ microg in the GH and placebo studies, respectively; P < 0.01). GH caused an upward shift of the FBF response to the endothelium-independent vasodilator sodium nitroprusside (P < 0.01), but did not affect the slope of the dose-response curve. GH infusion did not cause any appreciable increment in the venous IGF-I concentration in the test arm. In conclusion, GH acutely lowers peripheral vascular resistance and stimulates endothelial function. These effects are mediated by activation of the NO pathway and appear to be independent of IGF-I.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“most of the pituitary hormones have been shown to have important cerebral effects that impact not only brain development, but also allow normal brain function and are integral for effective brain repair and recovery.”
From Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury (2012) · cites this paper as [49]
In the citing paper
“it is now clear that there are both GH and insulinlike growth factor (IGF-1) receptors widely present in the brain.”
From Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury (2012) · cites this paper as [49]
In the citing paper
“GH has been shown to be directly involved in vascular reactivity, vascular tone and CNS repair processes after hypoxic injury”
From Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury (2012) · cites this paper as [49]
In the citing paper
“IGF-1 appears to be an important factor in myelination, re-myelination, prevention of demyelination and protection of oligodendrocytes from tumor necrosis factor-α induced apoptosis [47–56].”
From Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury (2012) · cites this paper as [49]
In the citing paper
“These hormones are also pivotal in maintaining the integrity and function of the cardiovascular and cerebrovascular systems (Bickel et al., 2023; Napoli et al., 2003; Scheepens et al., 2001; Silha et al., 2005; Tarantini et al., 2021a, 2021b; Norling et al., 2020; Kiss et al., 2022; Wagner et al., 2010).”
From Acute neuroendocrine changes after traumatic brain injury (2024) · cites this paper as Napoli et al., 2003
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Clinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723 · cited 1×
“intima media thickness of the large arteries (5).”
BackgroundSACCÀ, L., CITTADINI, A., & FAZIO, S. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-5-555 · Cited by 543
The Insulin-Like Growth Factor Axis: A Review of Atherosclerosis and Restenosis
Bayes-Genis, A., Conover, C. A., & Schwartz, R. S. (2000) · Circulation Research · doi:10.1161/01.res.86.2.125 · Cited by 416 · cited 3×
“A likely explanation for this difference is that in chronic GH deficiency, the function of VSMCs is also impaired as a consequence of structural alterations, which are corrected by long-term treatment with GH.”
BackgroundInfluentialClinical aspects of growth hormone deficiency in adults
de Boer, H. (1995) · Endocrine Reviews · doi:10.1210/er.16.1.63 · Cited by 402
Böger, R. H., Skamira, C., Bode-Böger, S. M., Brabant, G., von zur Muhlen, A., & Frolich, J. C. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119095 · Cited by 270 · cited 1×
“with pituitary disease (1, 2) or chronic heart failure (12, 13), which demonstrated the ability of GH to affect vascular function and NO bioavailability.”
BackgroundGrowth hormone acutely stimulates forearm muscle protein synthesis in normal humans
Fryburg, D. A., Gelfand, R. A., & Barrett, E. J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.3.e499 · Cited by 254 · cited 1×
“In a previous metabolic study the incidental observation was made that GH acutely accelerates FBF (10).”
BackgroundImpact of Hyperthyroidism and Its Correction on Vascular Reactivity in Humans
Napoli, R., Biondi, B., Guardasole, V., Matarazzo, M., Pardo, F., Angelini, V., Fazio, S., & Saccà, L. (2001) · Circulation · doi:10.1161/hc5001.100621 · Cited by 189 · cited 1×
“All subjects were studied in the morning after a 12- to 15-h overnight fast in a quiet room kept at 22–24 C, as previously described (6, 9).”
MethodSelf-citationGrowth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans
Fryburg, D. A., & Barrett, E. J. (1993) · Metabolism · doi:10.1016/0026-0495(93)90285-v · Cited by 145 · cited 1×
“This seems unlikely because a 6-h systemic infusion of GH at a rate even lower than the current one caused significant increments in systemic IGF-I (18).”
BackgroundMetabolic responses to exercise in young and older athletes and sedentary men
Hagberg, J. M., Seals, D. R., Yerg, J. E., Gavin, J., Gingerich, R., Premachandra, B., & Holloszy, J. O. (1988) · Journal of Applied Physiology · doi:10.1152/jappl.1988.65.2.900 · Cited by 138
Cited by
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Acromegaly: pathogenesis, diagnosis, and management
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V., & Melmed, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00244-3 · Cited by 279
Peptide Hormone Regulation of Angiogenesis
Clapp, C., Thebault, S., Jeziorski, M. C., & Martínez De La Escalera, G. (2009) · Physiological Reviews · doi:10.1152/physrev.00024.2009 · Cited by 191
“In addition, systemic (320) or local infusions of GH (390) acutely increase forearm blood flow and NO release in healthy humans without significantly raising plasma IGF-I levels or muscle IGF-I mRNA expression.”
BackgroundSystematic Review: The Effects of Growth Hormone on Athletic Performance
Liu, H., Bravata, D. M., Olkin, I., Friedlander, A., Liu, V., Roberts, B., Bendavid, E., Saynina, O., Salpeter, S. R., Garber, A. M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-10-200805200-00215 · Cited by 183
“Multiple articles were often published on the same study sample: 44 articles representing 27 unique study samples met our inclusion criteria (Table 1) (31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,…”
Hormonal modulation of endothelial NO production
Duckles, S. P., & Miller, V. M. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0797-1 · Cited by 175
“These effects of GH were not associated with any increase in IGF-1 levels in the forearm circulation [48, 68].”
Kelly, D. F., McArthur, D. L., Levin, H., Swimmer, S., Dusick, J. R., Cohan, P., Wang, C., & Swerdloff, R. (2006) · Journal of Neurotrauma · doi:10.1089/neu.2006.23.928 · Cited by 158
“…be directly involved in vascular reactivity, vascular tone, and CNS repair processes after hypoxic injury (D’Ercole et al., 1996; Hana et al., 2002; Napoli et al., 2003; Saatman et al., 1997; Scheepens et al., 2000, 2001; Silha et al., 2005; Ye and D’Ercole, 1999; Ye et al., 2002; Zhong et al.,…”
InfluentialMultiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?
Devesa, J., Almengló, C., & Devesa, P. (2016) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.4137/cmed.s38201 · Cited by 153
GH and the cardiovascular system: an update on a topic at heart
Isgaard, J., Arcopinto, M., Karason, K., & Cittadini, A. (2014) · Endocrine · doi:10.1007/s12020-014-0327-6 · Cited by 153
Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury
Dusick, J. R., Wang, C., Cohan, P., Swerdloff, R., & Kelly, D. F. (2012) · Pituitary · doi:10.1007/s11102-008-0130-6 · Cited by 121
Okamoto, T., Masuhara, M., & Ikuta, K. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00327.2007 · Cited by 104
“GH induces marked activation of the endothelium-dependent component of vasodilation, and the vascular effects of GH are linked to the activity of the NO pathway (24).”
BackgroundGrowth Hormone (GH) and Cardiovascular System
Caicedo, D., Díaz, Ó., Devesa, P., & Devesa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010290 · Cited by 108
“GH may have direct, non-IGF-I mediated, actions on endothelial cells, as the promotion of the expression and activity of eNOS [10,133].”
BackgroundAcute neuro-endocrine profile and prediction of outcome after severe brain injury
Olivecrona, Z., Dahlqvist, P., & Koskinen, L.-O. D. (2013) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/1757-7241-21-33 · Cited by 93
“2, (range 15–64), median ISS was 29 [9-43] and median GCS at intubation and sedation was 6 [3-8].”
BackgroundAcute gonadotroph and somatotroph hormonal suppression after traumatic brain injury
Wagner, J., Dusick, J. R., McArthur, D. L., Cohan, P., Wang, C., Swerdloff, R., Boscardin, W. J., & Kelly, D. F. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2009.1092 · Cited by 69
“…vascular tone, and CNS repair processes, while IGF-1 is critical in re-myelination and prevention of demyelination (D’Ercole et al., 1996; Hana et al., 2002; Napoli et al., 2003; Scheepens et al., 2001, 2000; Silha et al., 2005; Ye and D’Ercole, 1999; Ye et al., 2002; Zhong et al., 2005).”
Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis
Corvoisier, P. L., Hittinger, L., Chanson, P., Montagne, O., Macquin‐Mavier, I., & Maison, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1313 · Cited by 75
Role of IGF-1 in glucose regulation and cardiovascular disease
Abbas, A., Grant, P. J., & Kearney, M. T. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.8.1135 · Cited by 65
Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer
Kopchick, J. J., Basu, R., Berryman, D. E., Jørgensen, J. O. L., Johannsson, G., & Puri, V. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00702-6 · Cited by 61
Endocrine Disorders and Cardiovascular Disease
Klein, I. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00086-x · Cited by 54
Characterisation of a functional intronic polymorphism in the human growth hormone (GHI) gene
Millar, D. S., Horan, M. P., Chuzhanova, N. A., & Cooper, D. N. (2010) · Human Genomics · doi:10.1186/1479-7364-4-5-289 · Cited by 62
Heffernan, K. S., Fahs, C. A., Ranadive, S. M., & Patvardhan, E. A. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409354599 · Cited by 56
“Acute infusion of GH increases endothelial-dependent vasodilation.(72) Growth hormone contributes to the late phase of L-arginine-induced, NO-mediated vasodilation.”
Circulating endothelial progenitor cells: a new approach to anti-aging medicine?
Mikirova, N. A., Jackson, J. A., Hunninghake, R., Kenyon, J., Chan, K. W. H., Swindlehurst, C. A., Minev, B., Patel, A. N., Murphy, M. P., Smith, L., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-106 · Cited by 45
“For example, growth hormone, which is used in "antiaging medicine" has been demonstrated to improve endothelial responsiveness in healthy volunteers [146], and patients with congestive heart failure [147], this appears to be mediated through mobilization of endothelial progenitor cells [148,149].”
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome
Devin, J. K., Nian, H., Celedonio, J. E., Wright, P., & Brown, N. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz028 · Cited by 42
Coupal, K. E., Heeney, N. D., Hockin, B. C. D., Ronsley, R. J., Armstrong, K. R., Sanatani, S., & Claydon, V. E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01197 · Cited by 49
Frara, S., Loli, P., Allora, A., Santini, C., di Filippo, L., Mortini, P., Fleseriu, M., & Giustina, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09672-y · Cited by 44
Li, G., del Rincon, J. P., Jahn, L. A., Wu, Y., Gaylinn, B. D., Thorner, M. O., & Liu, Z. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2021 · Cited by 42
“J Clin Endocrinol Metab, April 2008, 93(4):1379–1385 jcem.”
BackgroundInfluentialGonzález, C., Rosas-Hernández, H., Jurado-Manzano, B. B., Ramirez-Lee, M. A., Salazar-Garcia, S., Martinez-Cuevas, P. P., Velarde‐Salcedo, A. J., Morales‐Loredo, H., Espinosa‐Tanguma, R., Ali, S. F., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.159 · Cited by 38
Opioids in Cardiovascular Disease: Therapeutic Options
Rawal, H., & Patel, B. M. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418757009 · Cited by 36
Wallace, J. D., & Cuneo, R. C. (2005) · Wiley eBooks · doi:10.1002/9780470757826.ch36 · Cited by 33
Cozzolino, D., Sasso, F. C., Cataldo, D., Gruosso, D., Giammarco, A., Cavalli, A., Maggio, C. D., Renzo, G., Salvatore, T., Giugliano, D., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2554 · Cited by 31
“shown to lower blood pressure and peripheral vascular resistance in humans by stimulating the endothelial nitric oxide pathway (24).”
BackgroundDevin, J. K., Blevins, L. S., Verity, D. K., Chen, Q., Bloodworth, J. R., Covington, J., & Vaughan, D. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0609 · Cited by 30
Cozzolino, D., Sasso, F. C., Salvatore, T., Torella, M., Cittadini, A., Gentile, S., Torella, R., & Giugliano, D. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.029 · Cited by 27
Setola, E., Monti, L. D., Lanzi, R., Lucotti, P., Losa, M., Gatti, E., Galluccio, E., Oldani, M., Fermo, I., Giovanelli, M. A., et al. (2008) · Metabolism · doi:10.1016/j.metabol.2008.07.024 · Cited by 28
Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults
Devin, J. K., Vaughan, D. E., Blevins, L. S., Chen, Q., Covington, J. W., Verity, D. K., & Young, P. P. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2007.11.001 · Cited by 27
Angelini, F., Pagano, F., Bordin, A., Picchio, V., De Falco, E., & Chimenti, I. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00062 · Cited by 25
“According to this vision, endothelial responsiveness in both healthy subjects and patients with cardiac conditions has been improved by antiaging strategies based on administration of growth hormone (GH), which, among its many functions, has been reported to increase the number of circulating EPCs (17, 18).”
BackgroundSánchez‐Rivera, L., Ferreira‐Santos, P., Sevilla, M. A., Montero, M. J., Recio, I., & Miralles, B. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b03872 · Cited by 25
Shechter, M., Ginsberg, S., Scheinowitz, M., Feinberg, M. S., & Laron, Z. (2007) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2007.01.009 · Cited by 24
Acute neuroendocrine changes after traumatic brain injury
Magyar-Sumegi, Z. D., Stankovics, L., Lendvai-Emmert, D., Czigler, A., Hegedus, E., Csendes, M., Toth, L., Ungvari, Z., Buki, A., & Toth, P. (2024) · Brain and Spine · doi:10.1016/j.bas.2024.102830 · Cited by 23
“These hormones are also pivotal in maintaining the integrity and function of the cardiovascular and cerebrovascular systems (Bickel et al., 2023; Napoli et al., 2003; Scheepens et al., 2001; Silha et al., 2005; Tarantini et al., 2021a, 2021b; Norling et al., 2020; Kiss et al., 2022; Wagner et al.,…”
BackgroundThe impact of traumatic brain injury on pituitary function
Sundaram, N. K., Geer, E. B., & Greenwald, B. D. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.003 · Cited by 22
Caicedo, D., Devesa, P., Arce, V. M., Requena, J., & Devesa, J. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717745494 · Cited by 20
Caicedo, D., Devesa, P., Álvarez, C. V., & Devesa, J. (2020) · Cells · doi:10.3390/cells9040807 · Cited by 21
“The consequence is that intracellular calcium decreases leading to vascular relaxation and modification of the arterial tone [86,87], one of the most important action of NO and GH, demonstrated after the arterial infusion of the hormone [14].”
BackgroundResultNissel, R., Fischer, D., Puhlmann, A., Holdt-Lehmann, B., Mitzner, A., Petzsch, M., Körber, T., Tieβ, M., Schmidt, R., & Haffner, D. (2009) · Microvascular Research · doi:10.1016/j.mvr.2009.05.006 · Cited by 18
Miljić, D., Miljić, P., Doknić, M., Pekić, S., Stojanović, M., Cvijović, G., Micić, D., & POPOVIC, V. M. (2013) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2013.08.005 · Cited by 17
Giorgi, A. D., Marra, A. M., Iacoviello, M., Triggiani, V., Rengo, G., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., et al. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-02980-4 · Cited by 16
“The GH/IGF-1 axis acts during the post-infarct ventricular remodeling that results from myocyte apoptosis; it favors vasodilation through action on nitric oxide and it improves muscle performances [10].”
BackgroundSelf-citationBoschetti, M., Agosti, S., Albanese, V., Casalino, L., Teti, C., Bezante, G. P., Brunelli, C., Albertelli, M., & Ferone, D. (2016) · Endocrine · doi:10.1007/s12020-016-0951-4 · Cited by 18
Nyström, H. C., Klintland, N., Caidahl, K., Bergström, G. M. L., & Wickman, A. (2005) · BMC Physiology · doi:10.1186/1472-6793-5-17 · Cited by 12
“This may in turn lead to decreased total peripheral resistance [6,14], resulting in reduced MAP.”
BackgroundGrowth hormone regulates vascular function—what we know from bench and bedside
Thum, T., & Bauersachs, J. K. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0018-6 · Cited by 9
“In addition, the same group demonstrated acute regulation of vascular function in humans treated with GH [10].”
BackgroundInfluentialWilson, J. R., Brown, N. J., Nian, H., Yu, C., Bidlingmaier, M., & Devin, J. K. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008000 · Cited by 8
Herman, R., Janež, A., Mikhailidis, D. P., Poredoš, P., Blinc, A., Šabović, M., Studen, K. B., Gh, S., Anagnostis, P. G., Pl, A., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611269162231106042956 · Cited by 11
Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system
Dulce, R. A., Hatzistergos, K. E., Kanashiro‐Takeuchi, R. M., Takeuchi, L. M., Balkan, W., & Hare, J. M. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09939-0 · Cited by 9
“There is limited experimental evidence that GHRH exerts vasodilatory effects, whereas there is abundant literature supporting blood pressure reduction mediated by activation of the GH/insulin-like growth factor-I (IGF-I) axis in vivo [ 34, 35].”
Arcopinto, M., & Cittadini, A. (2014) · Frontiers of hormone research · doi:10.1159/000360559 · Cited by 10
Growth hormone and testosterone in heart failure therapy
Agarwal, M., Naghi, J. J., Philip, K. J., Phan, A., Willix, R., & Schwarz, E. R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.485615 · Cited by 7
“In addition, there is a reduction in systemic vascular resistance (SVR), which further increases cardiac output, particularly during exercise [11,36,41-45].”
BackgroundConcurrent Aerobic and Strength Training for Body Composition and Health
Wilhelm, E. N., & Pinto, R. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-75547-2_19 · Cited by 12
Growth Hormone (GH) Treatment Does Not Restore Endothelial Function in Children with GH Deficiency
Hoffman, R. P. (2008) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2008.21.4.323 · Cited by 6
Boysan, Ş. N., Kantarcı, F., Celik, O., Mihmanlı, İ., Gazioğlu, N., & Kadıoğlu, P. (2012) · Angiology · doi:10.1177/0003319711431879 · Cited by 7
Adverse events with usage of human growth hormone: a review
Branski, L. K., Thanedar, S., Deen, N., Cho, K. W., Liu, G., Hundeshagen, G., Herndon, D. N., & Sousse, L. E. (2025) · Discover Medicine · doi:10.1007/s44337-025-00474-8 · Cited by 5
“A possible mechanism linking GH therapy to adverse neurological symptoms such as headaches is vasodilation [127].”
Anabolic Deficiencies in Heart Failure
Napoli, R., D’Assante, R., Miniero, M., Salzano, A., & Cittadini, A. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.012 · Cited by 5
Self-citationHoushmandi, N., Najafipour, H., Joukar, S., Dabiri, S., Abbasloo, E., Abdi, E., & Safi, Z. (2016) · Cytokine · doi:10.1016/j.cyto.2016.03.010 · Cited by 4
Hypertension in growth hormone excess and deficiency
Mihai, G., & Korbonits, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00017-0 · Cited by 6
Growth hormone, vascular reactivity, and heart failure
Napoli, R. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0016-8 · Cited by 3
“Furthermore, GH-induced vasodilation could be inhibited by the coinfusion of the NO synthase inhibitor L-NGmonomethylarginine (L-NMMA) [27].”
BackgroundSelf-citationHormonal Therapy in the Treatment of Chronic Heart Failure
Napoli, R., Salzano, A., Bossone, E., & Cittadini, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.64122-4 · Cited by 3
Self-citationThe Role of Endogenous Opioids in Cardioprotection
Sirbu, C. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-45493-6_19 · Cited by 2
Cai, J., Shi, S., Wang, Y., Zhang, X. D., Wei, X., Wu, Y., Shi, Y., Li, B., & Hou, D. (2025) · International Journal of Genomics · doi:10.1155/ijog/9710652 · Cited by 2
OBSOLETE: Hormonal Therapy for Heart Failure
Cittadini, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64122-3 · Cited by 1
Skorupski, J. (2017) · Acta Biologica · doi:10.18276/ab.2017.24-10
“…stomach and digestive system, kidneys and excretory system, as well as lungs and respiratory tract (Nass et al., 1995; Merola et al., 1996; Parks et al., 1998; Waters et al., 1999; Frago et al., 2002; Napoli et al., 2003; Dattani, Preece, 2004; Biller, 2007; Krysiak, Okopień, 2007; Harvey, 2010).”
BackgroundMaimaituxun, G., Amano, T., Kenny, G. P., Mündel, T., Kajiki, M., Tagawa, K., Katagiri, A., Tanabe, Y., Watanabe, K., Nishiyasu, T., et al. (2024) · European Journal of Applied Physiology · doi:10.1007/s00421-024-05448-9 · Cited by 1
“…vasculature (Lobie et al. 1990), and local administration of GH to brachial artery has been shown to acutely increase forearm blood flow in humans (Napoli et al. 2003), as in the case of sweating, acute changes in skin interstitial fluid and blood GH may also play a role in mediating the…”
Anabolic Deficiencies in Heart Failure
Napoli, R., D’Assante, R., Miniero, M., Salzano, A., & Cittadini, A. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2021.12.003 · Cited by 1
Self-citationCardiovascular Aspects in Laron Syndrome Patients
Scheinowitz, M., Feinberg, M. S., Shechter, M., Laron, Z., & Kauli, R. (2010) · Springer eBooks · doi:10.1007/978-3-642-11183-9_33 · Cited by 1
“One possible explanation could be related to nitric oxide levels found to be activated/ released following GH administration (Boger et al. 1996; Napoli et al. 2003); however, the Laron syndrome patients are resistant to this hormone.”
BackgroundCardiovascular and Respiratory Systems
Tivesten, Å., & Isgaard, J. (2005) · Springer eBooks · doi:10.1007/0-387-26274-1_6
Liu, H., Bravata, D. M., Olkin, I., Liu, V. X., Roberts, B. K., Bendavid, E., Saynina, O., Salpeter, S. R., Garber, A. M., & Hoffman, A. R. (2008)
Einfluss von kombiniertem Ausdauer- und Krafttraining auf die Körperzusammensetzung und Gesundheit
Wilhelm, E. N., & Pinto, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-36310-8_19
Growth hormone (GH) benefits for the treatment of lower limbs ischemia
Caicedo, D. (2024) · Angiología · doi:10.20960/angiologia.00495
Dyrka, K., Jamsheer, A., Bartecki, M., Bobkowski, W., Pawelec-Wojtalik, M., Rajewska-Tabor, J., Tomaszewska, A., Balcerzak, J., Aniol, Z., Niedziela, M., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1377510 · Cited by 1
“Moreover, GH may directly act on endothelial cells through the promotion of the expression and activity of endothelial NO synthase (eNOS) (27).”
Ren, X., Su, J., Shi, W., Wang, J., & Yang, X. (2025) · Acta Neurologica Belgica · doi:10.1007/s13760-025-02948-z
“Beyond its role in growth, the GH-IGF1 axis contributes to neuroprotection and cardiovascular health [ 98– 103], making its dysfunction relevant to long-term TBI outcomes.”
Cardiovascular Effects of Growth Hormone: From Deficiency to Acromegaly
Neshat, N., Adrejiya, P., Khan, Z. M., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001194
Salom, L. P. (2011) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/1s5s-cs79
Metadata
- Authors
- Napoli, R., Guardasole, V., Angelini, V., D’Amico, F., Zarra, E., Matarazzo, M., & Saccà, L.
- Affiliations
- Federico II University Hospital (IT)
- Department of Internal Medicine and Cardiovascular Sciences, University Federico II, 80131 Naples, Italy
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06-01
- Volume
- 88
- Issue
- 6
- Pages
- 2817-2820
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2012840565
- Cited by
- 74
- References
- 21
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Keywords
- growth hormone, vascular function, systemic vascular resistance, forearm blood flow, nitric oxide, endothelial function, acetylcholine-induced vasodilation, sodium nitroprusside, insulin-like growth factor I, brachial artery
- MeSH terms
- Acetylcholine, Adult, Blood Vessels, Brachial Artery, Dose-Response Relationship, Drug, Double-Blind Method, Female, Forearm, Humans, Injections, Intra-Arterial, Male, Nitric Oxide, Plethysmography, Reference Values, Regional Blood Flow, Growth Hormone, Vascular Resistance, Vasodilator Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.